MARCHEX INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MARCHEX INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $90.29M | Mar 14, 2018 |
| FY2017 | Dec 31, 2016 | $129.55M | Mar 14, 2018 |
| FY2017 | Dec 31, 2015 | $143.01M | Mar 14, 2018 |
| FY2016 | Dec 31, 2014 | $173.60M | Mar 8, 2017 |
| FY2015 | Dec 31, 2013 | $147.84M | Mar 7, 2016 |
| FY2014 | Dec 31, 2012 | $132.79M | Mar 10, 2015 |
| FY2013 | Dec 31, 2011 | $138.73M | Mar 3, 2014 |
| FY2012 | Dec 31, 2010 | $97.57M | Mar 12, 2013 |
| FY2011 | Dec 31, 2009 | $93.26M | Mar 12, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.42M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $48.12M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $49.91M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $52.17M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $53.48M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $51.22M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $54.49M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $85.25M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $90.29M | Mar 18, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.24M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($4.95M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($9.91M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($8.25M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($4.39M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($38.45M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($4.04M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($2.68M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($6.09M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($84.07M) | Mar 14, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.72M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($4.45M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($9.64M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($8.15M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($11.80M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($44.06M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($13.96M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($3.89M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($6.36M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($83.90M) | Mar 14, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.75M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $12.41M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $15.36M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $14.36M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $16.11M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $21.00M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $17.88M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $15.42M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $18.09M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $28.45M | Mar 14, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.41M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($1.10M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($4.40M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($2.29M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($6.34M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($3.37M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $5.09M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $5.05M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.69M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($3.67M) | Mar 14, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $382.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.38M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $2.87M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.35M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.35M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $1.62M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.65M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.56M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $986.0K | Mar 14, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.68M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $43.20M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $47.48M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $56.79M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $65.83M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $76.93M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $124.50M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $113.06M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $123.82M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $128.27M | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.60M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $10.57M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $11.61M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $12.68M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $14.33M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $24.24M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $24.66M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $18.04M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $33.82M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $15.00M | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.09M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $32.63M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $35.87M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $44.11M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $51.50M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $52.69M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $99.84M | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $95.03M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $90.00M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $113.27M | Mar 18, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.56M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $17.56M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $17.56M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $17.56M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $17.56M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $17.56M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $32.33M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $24.44M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 14, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($331.41M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($326.18M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($321.23M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($311.32M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($303.08M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($298.69M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($260.24M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($256.20M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($253.71M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($247.58M) | Mar 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.94M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $12.77M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $14.61M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $20.47M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $27.09M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $33.85M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $41.73M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $45.23M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $104.19M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $103.95M | Mar 14, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 14, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 14, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2018 | $21.91M | Mar 13, 2020 |
| FY2017 | Dec 31, 2015 | $1.69M | Mar 14, 2018 |
| FY2016 | Dec 31, 2014 | $3.33M | Mar 8, 2017 |
| FY2014 | Dec 31, 2012 | $9.38M | Mar 10, 2015 |
| FY2013 | Dec 31, 2011 | $2.94M | Mar 3, 2014 |
| FY2012 | Dec 31, 2010 | $2.82M | Mar 12, 2013 |
| FY2011 | Dec 31, 2009 | $2.90M | Mar 12, 2012 |